Michigan House Bill HB4545

Michigan 2025-2026 Regular Session

• Introduced: 6/3/25
• Refer: 6/3/25

Caption

Human services: medical services; compliance with the prescription drug cost and affordability review act; require. Amends 1939 PA 280 (MCL 400.1 - 400.119b) by adding sec. 109o. TIE BAR WITH: HB 4544'25

Impact

The enactment of HB4545 would directly influence the current medical assistance framework in Michigan, particularly in how prescription drug pricing is managed within that framework. By requiring compliance with specific federal standards, the bill hopes to create a more structured approach to medication affordability, which could improve access and reduce the financial burden on individuals eligible for state assistance. This bill could be a critical step in reforming how state authorities review drug costs and implement measures to ensure affordability for low-income residents relying on medical assistance.

Summary

House Bill 4545 aims to amend the 1939 PA 280, commonly referred to as the Social Welfare Act in Michigan. The bill introduces Section 109o, which mandates that the state's medical assistance program must align with Section 12 of the Prescription Drug Cost and Affordability Review Act. This move is intended to enhance state compliance with federal standards while addressing the rising costs associated with prescription medications under the medical assistance program. The bill emphasizes the necessity of keeping prescription drug prices affordable for those reliant on state-funded healthcare.

Contention

While HB4545 presents an initiative towards better affordability of prescription drugs, there may be contention regarding the extent to which the state will implement these requirements, especially concerning budget allocations and the potential impact on pharmaceutical companies. Stakeholders such as healthcare providers, advocacy groups for patients, and pharmaceutical manufacturers could have varying perspectives on this bill. Some may view it as a positive stride towards ensuring that essential medications remain accessible, while others might express concerns over operational implications or the sustainability of state-funded medical assistance programs given the compliance costs.